Key result
Smooth muscle Lrp1 deletion in mice induced progressive aortic root dilation and aortic insufficiency, leading to secondary dilated cardiomyopathy.
Why the study?
Does smooth muscle Lrp1 deletion induce aortic insufficiency and cardiomyopathy in mice, and can captopril improve the hemodynamic changes?
Does smooth muscle Lrp1 deletion induce aortic insufficiency and cardiomyopathy in mice, and can captopril improve the hemodynamic changes?
Smooth muscle Lrp1 deficiency in mice causes aortic dilation and insufficiency leading to secondary cardiomyopathy, which can be mitigated by captopril, providing a novel model for Marfan-like valvular cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Provides novel mouse model of Lrp1-driven aortopathy with secondary cardiomyopathy; leaves open human translation and captopril effects.
Valvular disease is common in patients with Marfan syndrome and can lead to cardiomyopathy. However, some patients develop cardiomyopathy in the absence of hemodynamically significant valve dysfunction, suggesting alternative mechanisms of disease progression. Disruption of LDL receptor-related protein-1 (Lrp1) in smooth muscle cells has been shown to cause vascular pathologies similar to Marfan syndrome, with activation of smooth muscle cells, vascular dysfunction and aortic aneurysms. This study used echocardiography and blood pressure monitoring in mouse models to determine whether inactivation of Lrp1 in vascular smooth muscle leads to cardiomyopathy, and if so, whether the mechanism is a consequence of valvular disease. Hemodynamic changes during treatment with captopril were also assessed. Dilation of aortic roots was observed in young Lrp1-knockout mice and progressed as they aged, whereas no significant aortic dilation was detected in wild type littermates. Diastolic blood pressure was lower and pulse pressure higher in Lrp1-knockout mice, which was normalized by treatment with captopril. Aortic dilation was followed by development of aortic insufficiency and subsequent dilated cardiomyopathy due to valvular disease. Thus, smooth muscle cell Lrp1 deficiency results in aortic dilation and insufficiency that causes secondary cardiomyopathy that can be improved by captopril. These findings provide novel insights into mechanisms of cardiomyopathy associated with vascular activation and offer a new model of valvular cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Basford et al. (2013) studied Aortic insufficiency and cardiomyopathy. Smooth muscle Lrp1 deletion vs. Wild-type littermates (smLrp1+/+) was evaluated on Aortic root diameter at 30 weeks (mm) (p=<0.001). Smooth muscle Lrp1 deletion in mice induced progressive aortic root dilation and aortic insufficiency, leading to secondary dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: